Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

This was the stock's second consecutive day of losses.

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and ...

The FDA approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s existing Covid shot, Spikevax, does not currently face.

Federal regulators are asking Novavax NVAX2.09%increase; green up pointing triangle to complete an additional randomized clinical trial on its Covid-19 vaccine after previously delaying approval ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...